Leadership & Pay ·
Outlook Therapeutics announced that CFO Lawrence A. Kenyon mutually agreed to cease serving as Chief Financial…
OTLKOutlook Therapeutics, Inc.
Outlook Therapeutics announced that CFO Lawrence A. Kenyon mutually agreed to cease serving as Chief Financial Officer, Treasurer, Corporate Secretary, and Board member effective September 1, 2026. The Board appointed Kevin Lundquist as the new CFO, Treasurer, principal financial officer, and principal accounting officer on the same date. Lundquist receives a $450,000 annual base salary, a target bonus of 50% of base, and a special grant of 500,000 stock options. Kenyon will remain in a non-executive role through September 30, 2026, with severance including twelve months' salary, full target bonus acceleration, and COBRA coverage. The Board size is reduced to eight directors upon Kenyon's departure. Outlook Therapeutics operates in the biotechnology industry.